Thu, 06th Oct 2016 11:23
LONDON (Alliance News) - Drug discovery company e-Therapeutics PLC Thursday said Non-Executive Director Trevor Jones subscribed for 41,204 new shares at 11.327 pence each on Wednesday.
Following the transaction, Jones holds 70,580 ordinary shares.
Admission of the new shares to trading on AIM is expected on October 12.
The stock was untraded at 9.01p Thursday.
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun
Copyright 2016 Alliance News Limited. All Rights Reserved.
(Sharecast News) - RNAi medicines data and development specialist e-Therapeutics proposed a fundraise and its delisting from AIM on Wednesday.
(Alliance News) - e-Therapeutics PLC on Wednesday announced its intention to cancel its admission to AIM and instead explore the option of listing on ...
e-Therapeutics PLC - Oxford, England-based computer-based drug discovery company - Says 2023 was
e-Therapeutics PLC - Oxford, England-based computer-based drug discovery company - Says that its shares will cease to trade on the OTCQX Best Market i...
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately report...